Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):66–69. doi: 10.1128/aac.39.1.66

Utilization of time-kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against Helicobacter pylori in stationary and logarithmic growth phases.

P E Coudron 1, C W Stratton 1
PMCID: PMC162486  PMID: 7695331

Abstract

Assessment of in vitro susceptibility testing of Helicobacter pylori is difficult because of the fastidious, slowly growing nature of this microorganism. The high rate of relapse observed clinically and a possible subpopulation of cells that are not actively replicating suggest the potential need for bactericidal therapy in order to eradicate H. pylori. We used modified time-kill kinetic methodology in order to evaluate the bactericidal activities of ampicillin and bismuth, alone and in combination, against three strains of H. pylori in both a stationary (slow) growth phase and a logarithmic (rapid) growth phase. We found that ampicillin produced a decrease in CFU per milliliter (2 to 4 log10 units) for three strains of H. pylori when tested in logarithmic growth phases but was less inhibitory (< 1-log10-unit decrease in CFU per milliliter) when tested in a stationary growth phase. In contrast, bismuth, when tested in a logarithmic growth phase, produced little inhibitory effect, as the CFU for all strains tested increased above the inoculum. However, when tested in a stationary growth phase, bismuth produced a decrease in CFU per milliliter of < 1 to > 3 log10 units). The activities of these two agents when combined mimicked the activity of the most active drug alone for that growth phase. We conclude that the clinical use of ampicillin combined with bismuth has been more effective than that of either agent used alone because ampicillin targets replicating cells, whereas bismuth targets cells that are not actively replicating.

Full Text

The Full Text of this article is available as a PDF (181.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armstrong J. A., Wee S. H., Goodwin C. S., Wilson D. H. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study. J Med Microbiol. 1987 Dec;24(4):343–350. doi: 10.1099/00222615-24-4-343. [DOI] [PubMed] [Google Scholar]
  2. Axon A. T. Helicobacter pylori infection. J Antimicrob Chemother. 1993 Jul;32 (Suppl A):61–68. doi: 10.1093/jac/32.suppl_a.61. [DOI] [PubMed] [Google Scholar]
  3. Blaser M. J. Helicobacter pylori: its role in disease. Clin Infect Dis. 1992 Sep;15(3):386–391. doi: 10.1093/clind/15.3.386. [DOI] [PubMed] [Google Scholar]
  4. Burette A., Glupczynski Y. On: The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol. 1991 Jul;86(7):924–925. [PubMed] [Google Scholar]
  5. Chiba N., Rao B. V., Rademaker J. W., Hunt R. H. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992 Dec;87(12):1716–1727. [PubMed] [Google Scholar]
  6. Coghill S. B., Hopwood D., McPherson S., Hislop S. The ultrastructural localisation of De-Nol (colloidal tripotassium dicitrato-bismuthate--TDB) in the upper gastrointestinal tract of man and rodents following oral and instrumental administration. J Pathol. 1983 Feb;139(2):105–114. doi: 10.1002/path.1711390203. [DOI] [PubMed] [Google Scholar]
  7. Cooreman M. P., Krausgrill P., Hengels K. J. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother. 1993 Jul;37(7):1506–1509. doi: 10.1128/aac.37.7.1506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coudron P. E., Kirby D. F. Comparison of rapid urease tests, staining techniques, and growth on different solid media for detection of Campylobacter pylori. J Clin Microbiol. 1989 Jul;27(7):1527–1530. doi: 10.1128/jcm.27.7.1527-1530.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. DeCross A. J., Marshall B. J., McCallum R. W., Hoffman S. R., Barrett L. J., Guerrant R. L. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol. 1993 Aug;31(8):1971–1974. doi: 10.1128/jcm.31.8.1971-1974.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Forbes G. M., Glaser M. E., Cullen D. J., Warren J. R., Christiansen K. J., Marshall B. J., Collins B. J. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994 Jan 29;343(8892):258–260. doi: 10.1016/s0140-6736(94)91111-8. [DOI] [PubMed] [Google Scholar]
  11. Glupczynski Y., Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol. 1990 Dec;85(12):1545–1551. [PubMed] [Google Scholar]
  12. Glupczynski Y., Burette A., Labbe M., Deprez C., De Reuck M., Deltenre M. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol. 1988 Apr;83(4):365–372. [PubMed] [Google Scholar]
  13. Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
  14. Graham D. Y. Campylobacter pylori and peptic ulcer disease. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):615–625. doi: 10.1016/s0016-5085(89)80057-5. [DOI] [PubMed] [Google Scholar]
  15. Graham D. Y., Lew G. M., Klein P. D., Evans D. G., Evans D. J., Jr, Saeed Z. A., Malaty H. M. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992 May 1;116(9):705–708. doi: 10.7326/0003-4819-116-9-705. [DOI] [PubMed] [Google Scholar]
  16. Konturek S. J., Radecki T., Piastucki I., Drozdowicz D. Advances in the understanding of the mechanism of cytoprotective action by colloidal bismuth subcitrate. Scand J Gastroenterol Suppl. 1986;122:6–10. doi: 10.3109/00365528609102578. [DOI] [PubMed] [Google Scholar]
  17. Korman M. G. Helicobacter pylori: fact or fiction? Scand J Gastroenterol Suppl. 1990;175:159–165. doi: 10.3109/00365529009093139. [DOI] [PubMed] [Google Scholar]
  18. Lambert J. R. Pharmacology of bismuth-containing compounds. Rev Infect Dis. 1991 Jul-Aug;13 (Suppl 8):S691–S695. doi: 10.1093/clinids/13.supplement_8.s691. [DOI] [PubMed] [Google Scholar]
  19. Lambert T., Mégraud F., Gerbaud G., Courvalin P. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother. 1986 Sep;30(3):510–511. doi: 10.1128/aac.30.3.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Langenberg W., Rauws E. A., Widjojokusumo A., Tytgat G. N., Zanen H. C. Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. J Clin Microbiol. 1986 Sep;24(3):414–417. doi: 10.1128/jcm.24.3.414-417.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Marshall B. J., Armstrong J. A., Francis G. J., Nokes N. T., Wee S. H. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 1987;37 (Suppl 2):16–30. doi: 10.1159/000199555. [DOI] [PubMed] [Google Scholar]
  22. Marshall B. J., Goodwin C. S., Warren J. R., Murray R., Blincow E. D., Blackbourn S. J., Phillips M., Waters T. E., Sanderson C. R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988 Dec 24;2(8626-8627):1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  23. Marshall B. J. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993 Mar;22(1):183–198. [PubMed] [Google Scholar]
  24. McNulty C. A., Dent J., Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985 Dec;28(6):837–838. doi: 10.1128/aac.28.6.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Megraud F., Trimoulet pascale, Lamouliatte H., Boyanova L. Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells. Antimicrob Agents Chemother. 1991 May;35(5):869–872. doi: 10.1128/aac.35.5.869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Millar M. R., Pike J. Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori. Antimicrob Agents Chemother. 1992 Jan;36(1):185–187. doi: 10.1128/aac.36.1.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. O'Riordan T., Mathai E., Tobin E., McKenna D., Keane C., Sweeney E., O'Morain C. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut. 1990 Sep;31(9):999–1002. doi: 10.1136/gut.31.9.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pelletier L. L., Jr, Baker C. B. Oxacillin, cephalothin, and vancomycin tube macrodilution MBC result reproducibility and equivalence to MIC results for methicillin-susceptible and reputedly tolerant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 1988 Mar;32(3):374–377. doi: 10.1128/aac.32.3.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rautelin H., Seppälä K., Renkonen O. V., Vainio U., Kosunen T. U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992 Jan;36(1):163–166. doi: 10.1128/aac.36.1.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  31. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  32. Rice L. B., Eliopoulos G. M., Moellering R. C., Jr In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother. 1989 Apr;33(4):470–473. doi: 10.1128/aac.33.4.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rokkas T., Sladen G. E. Bismuth: effects on gastritis and peptic ulcer. Scand J Gastroenterol Suppl. 1988;142:82–86. doi: 10.3109/00365528809091719. [DOI] [PubMed] [Google Scholar]
  34. Soll A. H. Pathogenesis of peptic ulcer and implications for therapy. N Engl J Med. 1990 Mar 29;322(13):909–916. doi: 10.1056/NEJM199003293221307. [DOI] [PubMed] [Google Scholar]
  35. Tytgat G. N., Rauws E. A. Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol Clin North Am. 1990 Mar;19(1):183–196. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES